How Cosentyx Stacks Up Against Other PsA Treatments
Cosentyx (secukinumab), an IL-17A inhibitor, targets inflammation in psoriatic arthritis (PsA) by blocking a key cytokine driving joint and skin symptoms. It shows high efficacy in reducing joint pain, skin plaques, and enthesitis compared to placebo, with ACR20 response rates around 50-60% at 24 weeks in trials like FUTURE studies.[1] Unlike traditional DMARDs, it acts faster on skin symptoms but requires subcutaneous injections.
Cosentyx vs. TNF Inhibitors Like Humira or Enbrel
TNF blockers like adalimumab (Humira) or etanercept (Enbrel) were first-line biologics for PsA, achieving ACR20 rates of 40-50%.[2] Cosentyx often matches or exceeds them on skin clearance (PASI90: 60-70% vs. 40-50%) and enthesitis resolution, per head-to-head data from the MAXIMISE trial, where it was non-inferior for joints but superior for skin.[3] TNFs have broader approval history and oral switch options post-patent, but Cosentyx avoids TNF resistance in switchers—about 20-30% of patients fail TNFs first.[1]
How Does Cosentyx Compare to IL-23 Inhibitors Like Tremfya?
Tremfya (guselkumab), an IL-23 blocker, rivals Cosentyx in skin-focused PsA, with PASI100 rates over 50% at week 24 in DISCOVER trials.[4] Cosentyx edges out on rapid joint improvement (ACR50 by week 12 in 30-40%), while Tremfya shines longer-term for dactylitis. Both outperform TNFs in skin, but IL-23s like Tremfya have fewer injection-site reactions (5% vs. 10-15% for Cosentyx).[3][4]
Cosentyx Versus JAK Inhibitors Like Xeljanz or Rinvoq
Oral JAK inhibitors like tofacitinib (Xeljanz) or upadacitinib (Rinvoq) offer pill convenience over Cosentyx's injections, with similar ACR50 rates (30-40%) in SELECT-PsA trials.[5] Cosentyx provides better skin responses (PASI90: 60% vs. 40-50%) and lower serious infection risk (ORAL Surveillance flagged CV/thrombosis concerns for JAKs in older patients).[6] JAKs suit injection-averse patients but carry black-box warnings; Cosentyx fits TNF/JAK failures.
What About Older Options Like Methotrexate or Stelara?
Methotrexate (MTX), a cheap oral DMARD, hits ACR20 in 30-40% but lags on skin (PASI50: 20-30%) and needs combo with biologics often.[1] Stelara (ustekinumab), an IL-12/23 inhibitor, matches Cosentyx on joints (ACR20: 40-50%) but trails on enthesitis; PSUMMIT trials showed slower onset.[7] Cosentyx is preferred first-line biologic per EULAR guidelines for active skin involvement.[8]
Side Effects and Safety Differences
Cosentyx has upper respiratory infections (15-20%), candidiasis (3-5%), and rare IBD flares.[1] TNFs risk more TB reactivation; JAKs elevate shingles/CV events; IL-23s are cleanest on infections.[2][4][5] Long-term data show Cosentyx retains efficacy beyond 5 years with low discontinuation (10-15%).[3]
Cost and Access Factors
Cosentyx lists at $6,000-$7,000/month (U.S. wholesale), similar to Humira pre-biosimilars or Tremfya, but patient assistance caps copays at $5/month.[9] Biosimilars for TNFs (e.g., adalimumab-aqvh) drop prices 20-80%; Cosentyx patent expires ~2032 in major markets.[10]
[1] Cosentyx prescribing information, Novartis. https://www.cosentyx.com
[2] Mease PJ et al., Lancet 2014 (TNF meta-analysis). https://pubmed.ncbi.nlm.nih.gov/24602827/
[3] Nash P et al., Lancet 2021 (MAXIMISE trial). https://pubmed.ncbi.nlm.nih.gov/34077757/
[4] Deodhar A et al., Lancet 2022 (DISCOVER-2). https://pubmed.ncbi.nlm.nih.gov/35065712/
[5] Mease PJ et al., Lancet 2021 (SELECT-PsA 1). https://pubmed.ncbi.nlm.nih.gov/34077756/
[6] Ytterberg SR et al., NEJM 2023 (ORAL Surveillance). https://www.nejm.org/doi/full/10.1056/NEJMoa2109927
[7] Ritchlin C et al., Ann Rheum Dis 2014 (PSUMMIT). https://ard.bmj.com/content/73/6/990
[8] Smolen JS et al., Ann Rheum Dis 2022 (EULAR guidelines). https://ard.bmj.com/content/81/9/1169
[9] GoodRx pricing data, 2024. https://www.goodrx.com/cosentyx
[10] DrugPatentWatch.com, Secukinumab patents. https://www.drugpatentwatch.com/p/tradename/COSENTYX